141040-66-6

Basic information

• Product Name: 2,5-di-O-benzylmyoinositol
• Synonyms: 2,5-di-O-benzylmyoinositol
• CAS NO: 141040-66-6
• Molecular Formula: C₂₀H₂₄O₆
• Molecular Weight: 360.40096
• Mol File: 141040-66-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 532.9°Cat760mmHg
• Flash Point: 276.1°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 3.48E-12mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: 2,5-di-O-benzylmyoinositol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-di-O-benzylmyoinositol(141040-66-6)
• EPA Substance Registry System: 2,5-di-O-benzylmyoinositol(141040-66-6)

Safety Data

• Hazardous Substances Data: 141040-66-6(Hazardous Substances Data)

Usage

General Description

2,5-di-O-benzylmyoinositol is a chemical compound that is derived from myoinositol, which is a type of sugar alcohol. It is often used in organic synthesis and as a building block for the creation of other compounds. The benzyl group attached to the myoinositol molecule serves to protect the hydroxyl groups, making it more stable and less reactive in certain reactions. 2,5-di-O-benzylmyoinositol has potential applications in the pharmaceutical and agricultural industries, and it is being researched for its potential therapeutic properties, particularly in the treatment of conditions such as diabetes and cancer. Additionally, 2,5-di-O-benzylmyoinositol has shown promise in the development of new materials and drug delivery systems due to its unique chemical structure and properties.

InChI:InChI=1/C20H24O6/c21-15-17(23)20(26-12-14-9-5-2-6-10-14)18(24)16(22)19(15)25-11-13-7-3-1-4-8-13/h1-10,15-24H,11-12H2/t15-,16+,17-,18+,19?,20?

Upstream product

• 176798-27-9 1,6:3,4-bis-myo-inositol 
• 1410865-11-0 1,6:3,4-bis-[O-(2,3-dimethoxybutane-2,3-diyl)]-myo-inositol 
• 100-39-0 benzyl bromide 
• 1037435-71-4 1,6:3,4-bis-[O-(2,3-dimethoxybutane-2,3-diyl)]-2,5-di-O-phenylmethylmyo-inositol 
• 136986-12-4 1,3,4,6-tetra-O-allyl-myo-inositol 
• 142387-34-6 1,3,4,6-tetra-O-allyl-2,5-di-O-benzyl-myo-inositol 
• 23393-20-6 (+/-)-3-O-benzyl-1,2:4,5-di-O,O-cyclohexylidene-myo-inositol 
• 98906-25-3 (±)-1,2-O-isopropylidene-3,6-di-O-benzyl-myo-inositol 
• 130659-80-2 (4S,5R,6S)-4-Hydroxy-5,6-bis-(2-methoxy-ethoxymethoxy)-cyclohex-2-enone 
• 129662-34-6 (1S,4S,5R,6R)-5,6-Bis-(2-methoxy-ethoxymethoxy)-cyclohex-2-ene-1,4-diol 
• 129662-35-7 C₂₈H₃₈O₈ 
• 130659-82-4 (5S,6S)-5,6-Bis-(2-methoxy-ethoxymethoxy)-cyclohex-2-ene-1,4-dione 
• 129662-34-6 (+/-)-1,2,4/3-2,3-Di-O-(2-methoxyethoxymethyl)cyclohex-5-ene-1,2,3,4-tetrol 
• 104826-13-3 1D-4,5-di-O-allyl-3,6-di-O-benzyl-1-l-menthoxyacetyl-myo-inositol 

Downstream Products

• 115432-20-7 octabenzyl (±)-2,3,5,6-(1,4-di-O-benzyl-myo-inosityl)tetrakisphosphate 
• 651313-77-8 Phosphorous acid dibenzyl ester (1S,2S,3R,4R,5R,6S)-2,5-bis-benzyloxy-3,4,6-tris-(bis-benzyloxy-phosphanyloxy)-cyclohexyl ester 
• 114218-20-1 (+/-)-3-O-allyl-1,4-di-O-benzyl-myo-inositol 
• 114218-20-1 (+/-)-2-O-allyl-1,4-di-O-benzyl-myo-inositol 
• 98906-25-3 (±)-1,2-O-isopropylidene-3,6-di-O-benzyl-myo-inositol 
• 98906-25-3 (+/-)-1,4-di-O-benzyl-5,6-O-isopropylidine-myo-inositol 
• 16749-94-3 (+/-)-2,3,4,5,6-penta-O-acetyl-1-O-benzyl-myo-inositol 
• 141040-65-5 octabenzyl 1,3,4,6-(2,5-di-O-benzyl-myo-inosityl)tetrakisphosphate 
• 115184-71-9 (+/-)-1,3,4-tri-O-benzyl-myo-inositol 
• 131147-14-3 (+/-)-1,3,4,5-tetra-O-benzyl-myo-inositol 
• 142631-56-9 1,3,4,6-tetrakis-O-benzyl-myo-inositol 
• 1365626-51-2 L-(-)-5-acetyl-1,3,6-tri-O-benzyl-myo-inositol 
• 98906-30-0 (±)-1,3,6-tri-O-benzyl-myo-inositol 
• 501669-17-6 (±)-1,3,6-tri-O-benzyl-myo-inositol 

Relevant articles and documents

Synthesis of oligo(spiroketal)s by polycondensation of silyl ethers derived from naturally occurring myo-inositol with 1,4-cyclohexanedione

Oligo(spiroketal)s (OSKs) were synthesized from myo-inositol, a naturally occurring cyclic compound bearing six hydroxyl groups. The successful synthesis of OSKs was achieved using silyl ethers 2 derived from 1,4-di-O-alkylated myo-inositol 1 as monomers,

Design and synthesis of lipid-coupled inositol 1,2,3,4,5,6-hexakisphosphate derivatives exhibiting high-affinity binding for the HIV-1 MA domain

The precursor of Gag protein (Pr55Gag) of human immunodeficiency virus, the principal structural component required for virus assembly, is known to bind d-myo-phosphatidylinositol 4,5-bisphosphate (PIP2). The N-terminus of Pr55G

Tetrakisphosphates and Bispyrophosphates of myo-Inositol Derivatives as Allosteric Effectors of Human Hemoglobin: Synthesis, Molecular Recognition, and Oxygen Release

Various 2,5- and 1,4-substituted and unsubstituted myo-inositol tetrakisphosphates and bispyrophosphates were prepared following a general synthetic pathway. All final compounds were tested for their capability to induce oxygen release from human hemoglob